Stefan J. Barfeld, Alfonso Urbanucci, Harri M. Itkonen, Ladan Fazli , Jessica L. Hicks , Bernd Thiede , Paul S. Rennie , Srinivasan Yegnasubramanian, Angelo M. DeMarzo , Ian G. Mills
Prostate cancer (PCa) is the most common non-cutaneous cancer in men. The androgen receptor (AR), a ligand-activated transcription factor, constitutes the main drug target for advanced cases of the disease. However, a variety of other transcription factors and signaling networks have been shown to be altered in patients and to influence AR activity. Amongst these, the oncogenic transcription factor c-Myc has been studied extensively in multiple malignancies and elevated protein levels of c-Myc are commonly observed in PCa. Its impact on AR activity, however, remains elusive. In this study, we assessed the impact of c-Myc overexpression on AR activity and transcriptional output in a PCa cell line model and validated the antagonistic effect of c-MYC on AR-targets in patient samples. We found that c-Myc overexpression partially reprogrammed AR chromatin occupancy and was associated with altered histone marks distribution, most notably H3K4me1 and H3K27me3. We found c-Myc and the AR co-occupy a substantial number of binding sites and these exhibited enhancer-like characteristics. Interestingly, c-Myc overexpression antagonised clinically relevant AR target genes. Therefore, as an example, we validated the antagonistic relationship between c-Myc and two AR target genes, KLK3 (alias PSA, prostate specific antigen), and Glycine N-Methyltransferase (GNMT), in patient samples. Our findings provide unbiased evidence that MYC overexpression deregulates the AR transcriptional program, which is thought to be a driving force in PCa.
Tags
ChIP-seq
Antibody
H3K4me3 (C15410003)
H3K27ac (C15410174)
H3K27me3 (C15410195)
Share this article
Tweet
Published
April, 2017
The European Regional Development Fund and Wallonia are investing in your future.
Extension of industrial buildings and new laboratories.
